Optigenix International, Phoenix, AZ, a joint venture between DB Capital Management, a wholly owned subsidiary of Digital Bridge, and Optigene-X, have expanded the joint venture to include CampaMed, New York, NY. The new company, Garra Sciences, will be granted an exclusive license to distribute CampaMed’s patented product line as well as age management products designed by Optigene-X. The nutraceuticals distributed by the joint venture are comprised of proprietary nutritional formulas designed by physicians and genetic scientists, backed by research and clinical studies.